Zeer Apellis Pharmaceuticals / intent / apellis-pharmaceuticals

Apellis Pharmaceuticals

501-1000 employees·Waltham, Massachusetts, United States·apellis.com

Observed, not inferred · updated weekly

Buying intent

15 tracked signals | Top 12 topics are below | Marketing and Product are carrying most of it.

15signals · 30 days
12topics tracked
66.67%attributed to a team

Attention by team

LinkedIn activity, by team

Where Apellis Pharmaceuticals's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.

Pharmaceutical
Hiring
Artificial Intelligence
Patient Advocacy
Add-on security
Digital Transformation
Marketing
High40% of team Marketing to Pharmaceutical: High, 40% of this team's signals
High40% of team Marketing to Hiring: High, 40% of this team's signals
Marketing to Artificial Intelligence: no signal
Medium20% of team Marketing to Patient Advocacy: Medium, 20% of this team's signals
Marketing to Add-on security: no signal
Marketing to Digital Transformation: no signal
Product
Product to Pharmaceutical: no signal
Product to Hiring: no signal
Medium100% of team Product to Artificial Intelligence: Medium, 100% of this team's signals
Product to Patient Advocacy: no signal
Product to Add-on security: no signal
Product to Digital Transformation: no signal
Others
Others to Pharmaceutical: no signal
Others to Hiring: no signal
Medium33% of team Others to Artificial Intelligence: Medium, 33% of this team's signals
Others to Patient Advocacy: no signal
Medium33% of team Others to Add-on security: Medium, 33% of this team's signals
Medium33% of team Others to Digital Transformation: Medium, 33% of this team's signals
LowMediumHigh·  banded against the busiest pairing on this page

Topics being researched

30-day window

Every tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.

Pharmaceutical
LinkedIn
High volume
96%
last
22d ago
Hiring
LinkedIn
High volume
98%
last
18d ago
Artificial Intelligence
LinkedIn
High volume
96%
last
12d ago
Patient Advocacy
LinkedIn
Medium volume
96%
last
12d ago
Add-on security
LinkedIn
Medium volume
98%
last
18d ago
Digital Transformation
LinkedIn
Medium volume
98%
last
12d ago
Business Network
LinkedIn
Medium volume
98%
last
18d ago
Leadership Development
LinkedIn
Medium volume
98%
last
18d ago
Pharmacy Technician
LinkedIn
Medium volume
98%
last
18d ago
Data Integrity
LinkedIn
Medium volume
98%
last
12d ago
Social Proof
LinkedIn
Medium volume
98%
last
26d ago
Product Lifecycle Management
LinkedIn
Medium volume
98%
last
22d ago

Need intent for a specific topic or industry?

We track the full taxonomy across every account in the graph — including themes not shown on this page.

Talk to us

Who's active at Apellis Pharmaceuticals

verified title on file

Titles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.

Marketing2 active
Leadershipresearching Hiring
in
Others2 active
Leadershipresearching Data Integrity
in
Leadershipresearching Pharmacy Technician
in
Product1 active
Leadershipresearching Artificial Intelligence
in

Primary products / business lines

LinkedIn company profile

Apellis is now part of Biogen. Please follow along there for the latest news. In the coming weeks, this page will no longer be updated or monitored.

Top accounts researching Apellis Pharmaceuticals

names withheld on the public page

These are companies whose own people brought up Apellis Pharmaceuticals unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.

6,459 companies · 25,813 people are researching Pharmaceutical

Apellis Pharmaceuticals's own team shows 2 signals on this topic. No one outside Apellis Pharmaceuticals has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.

  • Hiring75,708 cos · 411,263 people
  • Artificial Intelligence151,426 cos · 839,012 people
Sign up to see which companies →

Buyer profile

company size · seniority

Company size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.

Unlock the buyer profile

Company-size breakdown and buyer seniority mix for accounts researching Apellis Pharmaceuticals.

Company size breakdown
Buyer seniority mix

Sign up to learn more

Create an account to explore buyer insights as they become available.

Sign up to learn more →

Buying committee functions

Employee job titles (LinkedIn)

Product — 2 people; Marketing — 1 person; IT — 1 person

What's been said

public posts by Apellis Pharmaceuticals's team

No public post naming Apellis Pharmaceuticals has surfaced in the past year, so this is what Apellis Pharmaceuticals's own team is posting about publicly — their topics, in their words.

LinkedIn

Heading into next week's Marcus Evans PharmaMarketing Summit & look forward to discussing launches that don't follow the textbook. Smaller patient populations, complex HCP networks, competitive transitions, and the gap between what gets debated in conference rooms and what actually moves (the needle for) a brand. #PharmaMarketing #LaunchLeadership #RareDisease #MKTSummit

May 2026
LinkedIn

Excited for this new chapter with Biogen and looking forward to continuing to make an impact for patients alongside an incredible team!

May 2026
LinkedIn

Heading to San Antonio for the 51st Annual Oncology Nursing Society (ONS) Congress. Looking forward to the learning, the inspiration, and the conversations with oncology nurses driving care forward. If you'll be there, send me a DM here on LinkedIn to connect or stop by the Apellis booth #220 to say hi! #ONSCongress2026 #OncologyNursing #CareInMotion #Apellis #PatientCare

May 2026
LinkedIn

https://lnkd.in/g9V5e-pQ Optum Rx just announced a more transparent PBM pricing model built around flat monthly fees instead of pricing tied to rebates, drug list prices, or prescription volume. If the old payer story was built around rebate math, the new story may need to work harder: clear clinical value, patient affordability, and measurable outcomes - which it already is today in some specialties. Does this move us across the board though - closer to true outcomes-based contracting, or does the same negotiation just shift upstream to net price? Spencer Champagne David Bower #MarketAccess #PBM #Pharma #GTN #ValueBasedContracting #PharmaMarketing

May 2026
LinkedIn

I am proud to share my latest achievement with my LinkedIn network! I earned my ACRP-CP® certification in clinical research from the Association of Clinical Research Professionals (ACRP). ACRP-CP® formally recognizes clinical research professionals of all types, regardless of their roles or functional activities on the clinical study team.

May 2026
LinkedIn

Heading to Fort Lauderdale next week for the Marcus Evans PharmaMarketing Summit (May 18-19) at the Ritz-Carlton. Kellee King-Campbell Ike S. Clara LeBlanc https://lnkd.in/gmv4HRtM Joining a panel on "Redefining launch leadership: the mindset, models & metrics of modern brand success." Great lineup: Dan Joyce , Erric Byrd , Jay Shah, PharmD Imtiaz Hussain Three questions I'm bringing into the room: 1. How do you measure launch momentum when the patient pool is small and HCP behavior is the rate-limiter? 2. What's actually changed about brand leadership post-pandemic, and what's just been rebranded? 3. Where do mindset and metrics pull in opposite directions, and how do you call it? #PharmaMarketing #LaunchLeadership #RareDisease #BrandStrategy

May 2026

About this data. Apellis Pharmaceuticals (apellis.com). Department attribution is 66.67%; remaining activity is grouped under Others. Updated 2026-10-03T14:00:03.490Z.

Not yet computedPer-team narrative summaries